ECSP23043458A - Inmunocitoquina para activar el receptor IL-10Ra humano y su uso - Google Patents

Inmunocitoquina para activar el receptor IL-10Ra humano y su uso

Info

Publication number
ECSP23043458A
ECSP23043458A ECSENADI202343458A ECDI202343458A ECSP23043458A EC SP23043458 A ECSP23043458 A EC SP23043458A EC SENADI202343458 A ECSENADI202343458 A EC SENADI202343458A EC DI202343458 A ECDI202343458 A EC DI202343458A EC SP23043458 A ECSP23043458 A EC SP23043458A
Authority
EC
Ecuador
Prior art keywords
immunocytokine
receptor
activate
human
methods
Prior art date
Application number
ECSENADI202343458A
Other languages
English (en)
Inventor
Sergei Andreevich Ageev
Iana Andreevna Smirnova
Pavel Andreevich Iakovlev
Vladimir Sergeevich Tsympilov
Dmitry Valentinovich Morozov
Elena Sergeevna Kolosova
Iuliia Viktorovna Evdokimovskaia
Stanislav Rudolfovich Evdokimov
Aleksey Vladimirovich Kononov
Valery Vladimirovich Solovyev
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020140807A external-priority patent/RU2810750C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of ECSP23043458A publication Critical patent/ECSP23043458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a una inmunocitoquina para activar el receptor IL-10R? humano. La invención se refiere además a ácidos nucleicos que codifican dicha inmunocitoquina, vectores de expresión, células huésped y métodos para producirlos, métodos para producir la inmunocitoquina, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada y otros compuestos terapéuticamente activos, métodos para tratar una enfermedad oncológica y los usos de la inmunocitoquina o de las composiciones farmacéuticas de la misma para tratar una enfermedad oncológica.
ECSENADI202343458A 2020-12-10 2023-06-09 Inmunocitoquina para activar el receptor IL-10Ra humano y su uso ECSP23043458A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020140807A RU2810750C2 (ru) 2020-12-10 Иммуноцитокин для активации IL-10Rα рецептора человека и его применение

Publications (1)

Publication Number Publication Date
ECSP23043458A true ECSP23043458A (es) 2023-07-31

Family

ID=81973601

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202343458A ECSP23043458A (es) 2020-12-10 2023-06-09 Inmunocitoquina para activar el receptor IL-10Ra humano y su uso

Country Status (21)

Country Link
US (1) US20240034764A1 (es)
EP (1) EP4259644A4 (es)
JP (1) JP2023553934A (es)
KR (1) KR20230118919A (es)
CN (1) CN117120461A (es)
AR (1) AR124310A1 (es)
AU (1) AU2021398529A1 (es)
CA (1) CA3201656A1 (es)
CL (1) CL2023001677A1 (es)
CO (1) CO2023007563A2 (es)
CR (1) CR20230243A (es)
EC (1) ECSP23043458A (es)
IL (1) IL303501A (es)
JO (1) JOP20230129A1 (es)
MA (1) MA61003B1 (es)
MX (1) MX2023006830A (es)
PE (1) PE20241070A1 (es)
PY (1) PY21108779A (es)
TW (1) TW202237631A (es)
UY (1) UY39562A (es)
WO (1) WO2022124950A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150645A1 (es) * 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2015117930A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
US20200353050A1 (en) * 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
EP3927728A2 (en) * 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins

Also Published As

Publication number Publication date
MA61003B1 (fr) 2024-12-31
CA3201656A1 (en) 2022-06-16
AU2021398529A9 (en) 2024-10-24
JOP20230129A1 (ar) 2023-06-08
EP4259644A1 (en) 2023-10-18
MX2023006830A (es) 2023-07-06
JP2023553934A (ja) 2023-12-26
CN117120461A (zh) 2023-11-24
WO2022124950A1 (en) 2022-06-16
US20240034764A1 (en) 2024-02-01
TW202237631A (zh) 2022-10-01
MA61003A1 (fr) 2023-10-31
KR20230118919A (ko) 2023-08-14
PE20241070A1 (es) 2024-05-13
AU2021398529A1 (en) 2023-06-29
CL2023001677A1 (es) 2024-01-19
CR20230243A (es) 2023-07-13
PY21108779A (es) 2022-08-11
IL303501A (en) 2023-08-01
EP4259644A4 (en) 2024-10-16
AR124310A1 (es) 2023-03-15
UY39562A (es) 2022-05-31
CO2023007563A2 (es) 2023-07-21

Similar Documents

Publication Publication Date Title
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
JOP20220225B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
MX2023007228A (es) Constructo de arn.
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
MX2020005235A (es) Celula humana transformada y uso de la misma.
MX2023007229A (es) Constructo de arn.
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
ECSP23043458A (es) Inmunocitoquina para activar el receptor IL-10Ra humano y su uso
MX2024010321A (es) Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos
MXPA05010575A (es) Peptacuerpo para el tratamiento del cancer.
AR041086A1 (es) Vacuna
MX2021013018A (es) Formulacion de arnm.